KMT2A and acute leukemia: Another Menin-MLL inhibitor that also will be tested in phase I clinical trials in patients with acute leukemias is JNJ-75,276,617, as a monotherapy (NCT04811560), and as a combinatorial agent with venetoclax and azacitidine (NCT05453903).